Found: 5
Select item for more details and to access through your institution.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
- By:
- Publication type:
- Article
Total therapy-based treatment for multiple myeloma—a single center experience.
- Published in:
- Annals of Hematology, 2010, v. 89, n. 1, p. 53, doi. 10.1007/s00277-009-0767-x
- By:
- Publication type:
- Article
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective.
- Published in:
- Oncologist, 2011, v. 16, n. 4, p. 388, doi. 10.1634/theoncologist.2010-0386
- By:
- Publication type:
- Article
Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
- Published in:
- Clinical Transplantation, 2012, v. 26, n. 5, p. E549, doi. 10.1111/ctr.12018
- By:
- Publication type:
- Article
Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center Series.
- Published in:
- Acta Haematologica, 2014, v. 132, n. 1, p. 39, doi. 10.1159/000354830
- By:
- Publication type:
- Article